Urogen Pharma Ltd. (URGN)
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago.
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.8 per share a year ago.
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer market, offering a non-surgical alternative, with strong clinical results and significant revenue potential. Jelmyto's commercial success in a smaller market supports confidence in Zusduri's launch, with analysts projecting URGN to reach profitability by 2027.
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Raghuram Selvaraju - H.C.
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.55 per share a year ago.
UroGen: Expect Rough Patch Before Strong Recovery In 2026
UroGen Pharma is revisited after a previous Strong Buy rating, with UroGen having increased ~95% since then. The article reflects on UroGen's RTGel technology, which supports JELMYTO and ZUSDURI, its two FDA-approved products. JELMYTO has grown its revenues, but they are starting to taper off.
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UroGen Pharma: Targeting Profits In 2027
UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy ratings and price targets between $31 and $47, reflecting optimism about the company's growth trajectory. Despite growing sales, UroGen continues to post net losses and will likely require a capital raise to support the Zusduri launch.
